Does Transcatheter Aortic-Valve Replacement (TAVR) improve mortality, symptoms, and valve hemodynamics compared to Surgical Aortic-Valve Replacement in high-risk patients?
High-risk patients in the PARTNER trial
Transcatheter Aortic-Valve Replacement (TAVR)
Surgical Aortic-Valve Replacement (surgery)
Mortality at 2-year follow-uphard clinical
At 2-year follow-up, TAVR remains a viable alternative to surgery in high-risk patients with similar mortality and symptom reduction, though paravalvular regurgitation is more frequent and associated with late mortality.
A 2-year follow-up of patients in the PARTNER trial supports TAVR as an alternative to surgery in high-risk patients. The two treatments were similar with respect to mortality, reduction in symptoms, and improved valve hemodynamics, but paravalvular regurgitation was more frequent after TAVR and was associated with increased late mortality. (Funded by Edwards Lifesciences; ClinicalTrials.gov number, NCT00530894.).
Building similarity graph...
Analyzing shared references across papers
Loading...
Susheel Kodali
Mathew Williams
Craig R. Smith
New England Journal of Medicine
Stanford University
University of British Columbia
Emory University
Building similarity graph...
Analyzing shared references across papers
Loading...
Kodali et al. (Mon,) studied this question.
www.synapsesocial.com/papers/69d56dd275589c71d767d0f1 — DOI: https://doi.org/10.1056/nejmoa1200384